Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00868907 · ClinicalTrials.gov registry record · Phase 1

Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food

A Phase 1 study, sponsored by Warner Chilcott.

Completed
Registry status
Phase 1
Development phase
101
Enrollment target

NCT00868907: Completed Phase 1 study, sponsored by Warner Chilcott.

NCT00868907 is a Phase 1 study that has completed, run by Warner Chilcott. The registered enrollment target is 101 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00868907, a Phase 1 study, has completed, sponsored by Warner Chilcott.

COMPLETED
Registry status
Phase 1
Development phase
101 participants
Enrollment target

Study Summary

Randomized, open-label, single dose, 3-treatment, 3-period crossover study, with a 14- to 17-day washout period between doses. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2 and 3), 3 treatment periods (4 days each), 1 washout period (14 to 17 days separating periods 1, 2 and 3), and exit procedures.

Interventions

  • DRUG 35 mg risedronate DR tablet

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2009-03
Est. Completion 2009-04
Phase Phase 1
Warner Chilcott

53 total trials

What the finished NCT00868907 record still lists

NCT00868907 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% higher).

The record links to 0 conditions, and to 1 intervention - of which 35 mg risedronate DR tablet is the first listed.

NCT00868907 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00868907 about?

NCT00868907 is a clinical study titled "Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food". Randomized, open-label, single dose, 3-treatment, 3-period crossover study, with a 14- to 17-day washout period between doses. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2 and 3), 3 treatment periods (4 days each), 1 washout period (14 to 17 d...

What is the current status of trial NCT00868907?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2009-03. Estimated completion is 2009-04.

What interventions are being tested in trial NCT00868907?

The interventions under investigation include: 35 mg risedronate DR tablet (DRUG).

Who is sponsoring clinical trial NCT00868907?

This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00868907's enrollment target sits among peer trials

101 546th of 2000 higher than 1,455 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04033497 · 101 participants · NA

    Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases

  • NCT05111574 · 101 participants · Phase 2

    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

  • NCT05984680 · 101 participants

    COPD Care Pathway Among Patients With Cancer

  • NCT06266299 · 101 participants · Phase 1

    A Study of KK2269 in Adult Participants With Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00868907, the US trial registry maintained by the National Library of Medicine. NCT00868907 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.